Padmanee Sharma - Jounce Therapeutics Insider

JNCE -- USA Stock  

USD 7.78  0.05  0.64%

Dr. Padmanee Sharma, M.D. Ph.D. is a cofounder of Jounce Therapeutics and currently serves as scientific director and professor in the departments of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center. Dr. Sharma is a medical oncologist and immunologist, and is currently the principal investigator of several immunotherapy clinical trials, which allow her to further investigate immune responses and pathways that are critical for eliciting antitumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field including a Department of Defense Idea Development Award, a Cancer Prevention Research Institute of Texas Individual Investigator Award, a National Institute of Health R01 Award and an AACRCRISU2C Immunotherapy dream team grant
Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University. She also holds a B.A. in biology and an M.A. in biotechnology from Boston University.

Management Efficiency

The company has return on total asset (ROA) of (6.42) % which means that it has lost $6.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (20.72) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 112 people.Jounce Therapeutics (JNCE) is traded on NASDAQ in USA. It is located in 780 Memorial Drive and employs 112 people.

Jounce Therapeutics Leadership Team

Barbara Duncan, Director, MBA
Luis Diaz, Director
Drew Pardoll, Founder, Ph.D
Deborah Law, Executive, Ph.D
Richard Murray, CEO, Ph.D
Kimberlee Drapkin, CFO
Robert Kamen, Director, Ph.D
Hugh Cole, Executive, MBA
Thomas Gajewski, Founder
Elizabeth Trehu, Executive
Robert Tepper, Director, Ph.D
Perry Karsen, Chairman
Padmanee Sharma, Founder, Ph.D
Cary Pfeffer, Director, MBA
Duncan Higgons, Director
James Allison, Founder, Ph.D

Stock Performance Indicators

Current Sentiment - JNCE

Jounce Therapeutics Investor Sentiment
Macroaxis portfolio users are indifferent in their judgment towards investing in Jounce Therapeutics. What is your judgment towards investing in Jounce Therapeutics? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.